[Long lasting normalization of uric acid after combination therapy with 300 mg allopurinol and 60 mg benzbromarone in patients with gout and hyperuricemia].
Lasting normalisation of uric acid levels after treatment of patients with gout and hyperuricaemia with a combination of 300 mg allopurinol and 60 mg benzbromarone A total of 210 patients (163 men, 47 women) with gout and hyperuricaemia was treated for three months with daily doses of 300 mg allopurinol and 60 mg benzbromarone. During the course of treatment, the uric acid levels decreased to 4.3 +/- 1.3 mg/dl in male, and 4.4 +/- 1.3 mg/dl in female patients. Both of these levels differ significantly from the initial levels (p less than 0.001). Three months after discontinuation of treatment, uric acid levels were 5.7 +/- 1.2 mg/dl in women, and 5.9 +/- 1.4 mg/dl in men, levels that again differed significantly from the initial levels (p less than 0.001); both levels were, however, within the therapeutic range of below 6.4 mg/dl.
Matzkies
F
F
Kurparkklinik Bad Neustadt/Saale.
D000493:Allopurinol / Q000008:administration & dosage*; D001553:Benzbromarone / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006073:Gout / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008297:Male; D014527:Uric Acid / Q000097:blood*
D014527:Uric Acid; D001553:Benzbromarone; D000493:Allopurinol
Lang anhaltende Normalisierung der Harnsäure nach einer Kombinationstherapie mit 300 mg Allopurinol und 60 mg Benzbromaron bei Patienten mit Gicht und Hyperurikämie.